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Type i interferons in Bacterial 
infections: A Balancing Act
Pavel Kovarik*, Virginia Castiglia, Masa Ivin and Florian Ebner
Max F. Perutz Laboratories, University of Vienna, Vienna, Austria
Defense against bacterial infections requires activation of the immune response as well 
as timely reestablishment of tissue and immune homeostasis. Instauration of homeosta-
sis is critical for tissue regeneration, wound healing, and host recovery. Recent studies 
revealed that severe infectious diseases frequently result from failures in homeostatic 
processes rather than from inefficient pathogen eradication. Type I interferons (IFN) 
appear to play a key role in such processes. Remarkably, the involvement of type I 
IFNs in the regulation of immune and tissue homeostasis upon bacterial insult may have 
beneficial or detrimental consequences for the host. The reasons for such ambivalent 
function of type I IFNs are not understood. The disparate effects of type I IFNs on bac-
terial infections are in marked contrast to their well-established protective roles in most 
viral infections. In this review, we will focus on type I IFN effector mechanisms which 
balance processes involved in immune and tissue homeostasis during specific bacterial 
infections and highlight the most important missing links in our understanding of type I 
IFN functions.
Keywords: type i interferon, bacterial infection, cytokines, chemokines, innate immunity, resilience to infections, 
immunomodulation, immunosuppression
iNTRODUCTiON
Successful defense against pathogens requires both, the eradication of the infectious agent by the 
immune system as well as tissue protection against the damaging effects of the immune response. 
Increasing evidence indicates that many if not most infectious diseases result from insufficient resil-
ience, i.e., from a failure of the infected host to repair and regenerate destroyed tissues, rather than 
from inefficient pathogen clearance (1–4). Mechanisms which preserve the integrity of host tissues 
during the intensive inflammatory response against the pathogen remain incompletely understood. 
Recent studies established that successful tissue protection during infection requires systems which 
balance the immune response as well as mechanisms which restore tissue homeostasis. These mecha-
nisms are often interdependent and result from messengers like growth factors, cytokines, or lipids 
produced by immune cells (1–4). Examples include the anti-inflammatory cytokine IL-10, the tissue 
regeneration promoting IL-22 and amphiregulin, the tissue remodeler TGF-β, or the pro-resolving 
lipid lipoxin (5–8). Remarkably, several recent studies demonstrated that type I interferons (IFNs) 
can also act as critical resilience-promoting cytokines during infections with several streptococcal 
species (9–11). Such protective functions are in marked contrast to detrimental effects of type I 
IFN during infections with many other bacterial species (12, 13). The reasons for the ambivalent 
roles of type I IFNs in bacterial infections remain poorly understood. However, it appears that the 
ability of type I IFNs to both suppress and stimulate immune responses is of critical importance 
TABle 1 | effects of type i interferons (iFN) signaling in bacterial infections.
Pathogen Type of 
bacteria
Route of infection Model of infection effect of 
type i iFN 
signaling
Mechanism Reference
Streptococcus 
pneumoniae
Gram+, 
extracell
Intranasal; intratracheal Model of lung infection Protective Protection against epithelial barrier 
damage
(10, 11, 14)
Streptococcus 
pyogenes
Gram+, 
extracell
Subcutaneous Model of invasive 
cellulitis
Protective Prevention of IL-1β-driven systemic 
hyperinflammation
(9, 15)
Group B 
streptococcus
Gram+, 
extracell
Intraperitoneal (adults); 
subcutaneous (neonates)
Model of systemic 
infection/sepsis
Protective Protection against bacteremia (16, 17)
Legionella 
pneumophilia
Gram−, 
intracell
Intranasal Model of lung infection Protective Inhibition of intracellular replication of 
the pathogen and protection against 
bacteremia
(18, 19)
Helicobacter pylori Gram−, 
extracell
Oral Stomach infection/
gastric mucosa infection
Protective Induction of CXCL10 and reduction 
of bacterial burden in gastric mucosa
(20)
Staphylococcus 
aureus
Gram+, 
extracell
Intranasal Model of lung infection Detrimental Exacerbated inflammatory cytokine 
production and leukocyte recruitment
(14, 21)
Mycobacterium 
tuberculosis
Intracell Aerogenic Model of lung infection Detrimental Immunosuppression (inhibition of 
IL-1 production and Th1 responses)
(22–24)
Listeria 
monocytogenes
Gram+, 
intracell
Tail vein injection Model of systemic 
infection
Detrimental Induction of apoptosis (25, 26)
Intraperitoneal Model of systemic 
infection
Detrimental Induction of apoptosis in the spleen 
and supression of IFN-γ production
(27, 28)
Tail vein injection Model of systemic 
infection
Detrimental Suppression of IFNGR expression (29)
Intragastric Model of gastrointestinal 
infection
Protective Upregulation of protective cytokines 
limits hepatic inflammation
(28)
Through food Model of gastrointestinal 
infection
No effect (30)
Francisella tularensis 
subspecies tularensis
Gram−, 
intracell
Intranasal Model of tularemia Detrimental Inhibition of IL-17A (31)
Francisella tularensis 
subspecies novicida
Gram−, 
intracell
Intradermal Model of intradermal 
infection
Detrimental Induction of macrophage death, 
inhibition of IL-17A and increased 
bacterial loads
(31, 32)
Salmonela enterica 
serovar Typhimurium
Gram−, 
intracell
Tail vein injection; 
intraperitoneal
Model of systemic 
infection
Detrimental Enhancement of macrophage 
necroptosis and failure to control 
baterial burden
(33)
Oral Model of gastrointestinal 
infection
Detrimental Immunosppression (inhibition of 
IL-1β, CXCl1 and CXCL2)
(34)
Coxiella burnetii Gram−, 
intracell
Intratracheal Model of lung infection Detrimental Promotion of dissemination (35)
Intratracheal infection 
with intraperitoneal rIFNα 
administration
Model of lung infection Detrimental Inhibition of inflammatory response 
in lungs
Intratracheal infection 
with intratracheal rIFNα 
administration
Model of lung infection Protective Reduction in bacterial dissemination
Postinfluenzal 
bacterial pneumonia
Intratracheal; 
oropharyngeal aspiration
Model of lung infection Detrimental Attenuation of inflammatory response 
and leukocyte recruitment
(36–39)
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(Table 1; Figure 1). This review focuses on the role of type I IFNs 
in balancing pro- and anti-inflammatory processes as well as cell 
survival and cell death programs during antibacterial defense and 
discusses how these effects determine the outcome of an infection.
TYPe i iFN iNDUCTiON BY BACTeRiA
Type I IFNs were described more than a half century ago as 
products which are secreted by virus-infected cells and interfere 
FigURe 1 | Mechanisms of action and effects of type i interferons (iFNs) during infection with bacterial pathogens. Arrow-headed lines represent 
stimulation and bar-headed lines represent inhibition by type I IFNs. Pathogen abbreviations: Spn, Streptococcus pneumoniae; Spy, Streptococcus pyogenes; 
GBS, Group B Streptococcus; Cb, Coxiella burnetii; Lm, Listeria monocytogenes; Hp, Helicobacter pylori; Lp, Legionella pneumophilia; Sa, Staphylococcus 
aureus; Ftn, Francisella tularensis subspecies novicida; Ftt, Francisella tularensis subspecies tularensis; Mt, Mycobacterium tuberculosis; St, Salmonella enterica 
serovar Typhimurium.
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with virus replication in autocrine and paracrine ways (40). It is 
now known that type I IFNs are cytokines produced in response 
to viral, bacterial, and fungal pathogens, as well as parasites. The 
effector mechanisms of type I IFNs mainly derive from products 
of genes which are transcriptionally regulated by type I IFN 
signaling. Type I IFNs induce hundreds of interferon-stimulated 
genes (ISGs) through activation of the homodimeric STAT1 and 
the heterotrimeric STAT1–STAT2–IRF9 (i.e., ISGF3) transcrip-
tion factors (41). Bacteria trigger type I IFN production mostly 
following the recognition of bacterial nucleic acids or the 
Gram-negative cell wall component lipopolysaccharide (LPS) by 
innate immune receptors (12, 42). The induction mechanisms 
have been best studied for IFN-β which belongs together with 
IFNα4 to the first type I IFNs produced during infection and 
is the driver of other type I IFN genes (43, 44). The induction 
of IFN-β by bacterial DNA is complex and involves different 
pathways. The most common mode of IFN-β induction by 
bacterial DNA is through the cytosolic DNA sensor cyclic GMP-
AMP synthase, as described for Francisella novicida, group B 
streptococcus (GBS) (Streptococcus agalactiae), Legionella pneu-
mophila, Listeria monocytogenes, Mycobacterium tuberculosis, 
and Neisseria gonorrhoeae (45–51). The cytosolic DNA sensor 
Ifi204 (IFI16 in humans) contributes to IFN-β induction in the 
course of F. novicida and L. monocytogenes (48, 49). The signaling 
events downstream of these DNA sensors involve the STING–
TBK1–IRF3 pathway driving the IFN-β gene transcription. 
L. monocytogenes can activate this pathway also independently 
of DNA sensing. This alternative mechanism is driven by 
binding of the bacterial product c-di-AMP to STING (51, 52). 
The recognition of bacterial DNA through unmethylated CpG 
motif-containing DNA by the endosomal Toll-like receptor 9 
can also contribute to IFN-β induction, although the importance 
and relevance of this pathway in the context of the overall IFN-β 
production and host response have not been entirely clarified 
(42). Bacterial RNA has been recently established as another key 
IFN-β inducer. A short and highly conserved sequence found in 
the bacterial 23S rRNA is recognized by the mouse TLR13 lead-
ing to Myd88- and IRF5-dependent IFN-β induction (9, 53–56). 
Human cells employ TLR8 as IFN-β-inducing RNA sensor 
rather than TLR13 which is missing in humans (9, 53, 57–59). 
The precise nature of bacterial RNA triggering the human TLR8 
remains to be identified.
IFN-β induction by LPS occurs after binding of this ligand to 
the TLR4 and the following internalization into the endosome 
(60). Subsequently, a TRIF-dependent activation of the kinase 
TBK1 causes phosphorylation of the transcription factor IRF3 
to stimulate IFN-β gene transcription. Endosomal signaling has 
been also implicated in IFN-β induction by TLR2 in response to 
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Gram-positive bacteria, although this mechanism appears to be 
restricted to specific immune cells and/or pathogens (61–63). 
The cytosolic receptors NOD1 and NOD2 were reported to 
trigger IFN-β production following infection with Helicobacter 
pylori and M. tuberculosis, respectively (20, 64). NOD2 engage-
ment can induce IFN-β also in responses to Staphylococcus 
aureus (14).
While the pathways causing IFN-β induction by bacteria are 
relatively well understood, more studies are needed to assess 
the importance of individual pathways for the overall IFN-β 
production in whole organism rather than cells. One of the rare 
studies on this topic revealed that the dominant IFN-β-inducing 
pathway during infection with Streptococcus pyogenes (group A 
streptococcus) is the TLR13-mediated RNA recognition path-
way (9).
Additional work is also needed to clarify the key IFN-β 
producing cells, as investigated during, e.g., L. monocytogenes 
infections (65–67) and the reported cell type-specific features of 
IFN-β induction (12, 15, 16).
TiPPiNg THe BAlANCe i: BeNeFiTS 
OF iMMUNOMODUlATORY eFFeCTS 
OF TYPe i iFN SigNAliNg DURiNg 
BACTeRiAl iNFeCTiONS
Type I IFNs’ ability to stimulate immune responses against 
viruses has been established very early after their discovery but 
it soon became clear that these cytokines exhibit also immuno-
suppressive activities. The first evidence for such immunosup-
pressive activities was provided in a study showing that type I 
IFNs were able to reduce carrageenin-induced footpad swelling 
(68). Thus, type I IFNs are now regarded as immunomodula-
tory cytokines capable of enhancing or dampening the immune 
response, depending on the context. This ambiguousness 
contributes to the disparate and still incompletely understood 
roles of type I IFNs during bacterial infections. Importantly, no 
unifying principles have been found to date: neither the ben-
eficial nor detrimental effects of type I IFN signaling correlate 
with the broad pathogen classification into Gram-positive and 
-negative, extra- and intracellular pathogens, or the route of 
infection (Table 1; Figure 1).
Immunosuppressive effects of type I IFN signaling are benefi-
cial during infection with the Gram-positive largely extracellular 
human pathogen S. pyogenes (9). S. pyogenes is the causative agent 
of mild (e.g., pharyngitis and scarlet fever) but also invasive and 
life-threatening infections (e.g., cellulitis, necrotizing fasciitis, 
and streptococcal toxic shock syndrome). Mice deficient in the 
type I IFN receptor IFNAR1 are more susceptible to subcutaneous 
S. pyogenes infection, which is a relevant model of severe invasive 
infection of the soft tissue (15). Type I IFN signaling promotes 
resistance against S. pyogenes by suppressing the transcription 
of the Il1b gene (9). The absence of type I IFN signaling results 
in an unrestricted production of IL-1β thereby causing a lethal 
hyperinflammation and organ damage. Importantly, type I IFN 
signaling balances rather than prevents Il1b transcription so that 
a controlled and life-saving IL-1β production is achieved (9). The 
key IFN-β producer and effector cells in this infection model are 
both LysM+ and CD11c+ myeloid cells (9).
Immunomodulation by type I IFN signaling is protective 
during infection with the human Gram-positive extracellular 
pathogen GBS (16, 17). GBS is regarded as commensal microbe 
asymptomatically colonizing the skin and mucosal tissues of 30% 
people, yet it is the leading cause of severe neonatal pneumonia 
and meningitis in developed countries. The absence of IFNAR1 
results in increased bacterial loads during both subcutaneous 
GBS infection of neonate mice and intravenous infection of 
adult animals (16, 17). Similarly, type I IFN signaling is protec-
tive against uncontrolled bacteremia during infection with the 
Gram-negative intracellular bacterium L. pneumophila, which is 
a frequent cause of the severe pneumonia, Legionnaire’s disease 
(18). Type I IFN signaling inhibits in a cell-autonomous way 
replication of L. pneumophila inside the infected cell (18, 19). 
The organismal physiology of the protective effects of type I IFN 
signaling during infection with GBS and L. pneumophila remains 
to be elucidated so that it is presently unclear whether immuno-
suppressive or immunostimulatory effects of type I IFNs drive the 
resistance against these two pathogens.
Stimulation of the immune response by type I IFN signaling 
is advantageous in defense against the Gram-negative pathogen 
H. pylori (20). H. pylori is a frequent cause of chronic gastritis 
and is associated with increased risk of gastric ulcers and stom-
ach cancer. Deficiency in type I IFN signaling causes increased 
H. pylori loads in the stomach of orally infected mice. The lack 
of type I IFN responses is associated with decreased levels of the 
chemokine CXCL10 suggesting that type I IFNs promote defense 
against H. pylori by stimulating CXCL10-driven inflammation 
(20). Immunostimulatory effects of type I IFNs are beneficial 
also during gastric infection with the food-borne Gram-positive 
intracellular pathogen L. monocytogenes (28). L. monocytogenes 
infects the gastrointestinal tract, where it traverses the epithelial 
barrier and spreads into distant organs. Deficiency in type I 
IFN signaling results in an increased bacterial dissemination 
and is accompanied by diminished production of several pro-
inflammatory cytokines, including TNF and IL-6 upon gastric 
infection using oral gavage (28). Interestingly, type I IFN signal-
ing plays no role in an infection model using food contaminated 
with L. monocytogenes (30).
TiPPiNg THe BAlANCe ii: 
DiSADvANTAgeS OF 
iMMUNOMODUlATORY eFFeCTS 
OF TYPe i iFN SigNAliNg DURiNg 
BACTeRiAl iNFeCTiONS
Immunosuppression by type I IFN signaling is detrimental dur-
ing infection with the intracellular pathogen and causative agent 
of tuberculosis, M. tuberculosis (22–24). Type I IFN signaling-
mediated inhibition of IL-1 cytokines during M. tuberculosis 
lung infection blunts the antimicrobial defense and results in 
increased local as well as systemic bacterial loads (24). The key 
type I IFN effector cells are transplantable inflammatory mono-
cyte-macrophage cells and DCs (24). The precise mechanism of 
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IL-1 inhibition by type I IFN signaling in this infection model is 
not resolved but includes both direct as well as indirect mecha-
nisms (24). The indirect IL-1 inhibition appears to be mediated 
by the anti-inflammatory cytokine IL-10 which is known to be 
upregulated by type I IFNs (69). The importance of type I IFN 
signaling in M. tuberculosis infections is underlined by type I IFN 
signaling-associated gene expression pattern found in blood cells 
of patients with active tuberculosis (70). The detrimental func-
tion of type I IFN signaling during M. tuberculosis lung infection 
is converted into a protective one if IFN-γ signaling is missing 
(71). Under such conditions, type I IFNs inhibit the polarization 
of macrophages into infection-permissive alternatively activated 
macrophages.
Inhibition of immune response by type I IFNs is deleteri-
ous during infection with the facultative intracellular Gram-
negative bacterium F. novicida (31). F. novicida is a subspecies 
of Francisella tularensis which infects humans through the skin 
or aerosol droplets and causes ulceroglandular or pneumonic 
tularemia, respectively. IFNAR1-deficient mice infected intra-
dermally with F. novicida respond by an increased IL-17 produc-
tion compared to WT animals and, correspondingly, are more 
resistant against infection (31). Similar increase in resistance is 
also observed during lung infection with F. tularensis (31). The 
key IL-17 producers during F. novicida infection are IL-17A+ γδ 
T cells which show enhanced expansion in the absence of type 
I IFN signaling.
Interferon-β exacerbates infection with S. typhimurium by 
reducing the ability of the host to launch a complete immune 
response (34). S. typhimurium is Gram-negative intracellular 
pathogen associated with gastroenteritis in humans and a severe 
disease resembling typhoid fever in mice. Mice deficient in IFN-
β are more resistant against oral infection with S. typhimurium 
and display enhanced expression of IL-1β and the neutrophil 
chemoattractants, CXCL1 and CXCL2 (34). These changes are 
attributable to IFN-β-mediated inhibition of these genes in 
macrophages and are independent of S. typhimurium-induced 
macrophage death.
Listeria monocytogenes-induced type I IFN signaling down-
regulates the expression of both type II IFN receptor subunits, 
IFNGR1 and IFNGR2, thereby decreasing the responsiveness 
of macrophages and DCs to IFN-γ (29). The suppression of the 
IFN-γ signaling results in an increased susceptibility to L. mono-
cytogenes infection. Increased susceptibility to L. monocytogenes 
infection is also caused by type I IFN-mediated induction of 
anti-inflammatory IL-10 (72).
Immunosuppressive effects of type I IFNs are harmful dur-
ing postinfluenzal bacterial pneumonia (36–39). The immune 
response during a secondary postinfluenzal infection with the 
Gram-positive extracellular pathogen S. pneumoniae, a key 
causative agent of pneumonia, is impaired. This is caused by the 
ability of type I IFNs to suppress production of the neutrophil 
chemoattractants CXCL1 and CXCL2, the macrophage chemoat-
tractant CCL2, and the inflammation-promoting cytokine IL-17 
(36–38). The resulting reduction of leukocyte infiltration in the 
lung diminishes the capability of the host to control bacterial 
growth. Similar alterations in the immune response appear 
to be responsible for the increased susceptibility of mice to 
postinfluenzal infection with S. aureus and Pseudomonas aerugi-
nosa (39). The mechanisms of the immunosuppressive effects of 
type I IFN signaling during postinfluenzal bacterial infection are 
not well understood but they might act downstream of the type I 
IFN-mediated inhibition of IL-1 cytokines.
Enhancement of the inflammatory response is associated with 
detrimental effects of type I IFN signaling during lung infection 
with the Gram-positive extracellular pathogen S. aureus (21). 
IFNAR1-deficient mice exhibit a lower TNF and IL-6 produc-
tion and decreased leukocyte infiltration in the lung compared 
to WT animals suggesting that type I IFN signaling causes an 
exacerbated tissue damage (21). The pathogenicity of S. aureus 
strains correlates with the levels of type I IFNs induced during 
infection with differently virulent strains (14).
TiPPiNg THe BAlANCe iii: RegUlATiON 
OF TiSSUe AND Cell iNTegRiTY BY 
TYPe i iFNs DURiNg BACTeRiAl 
iNFeCTiONS
Type I IFN signaling plays an indispensable role in the preserva-
tion of the epithelial barrier and epithelial integrity during lung 
infection with S. pneumoniae (10, 11). Type I IFN signaling 
promotes the maintenance of lung epithelial tight junctions 
during S. pneumoniae infection thereby reducing the passage 
of the pathogen from alveoli into the lung parenchyma (10). 
IFNAR1-deficient mice display increased permeability of the lung 
epithelium and enhanced invasiveness of S. pneumoniae infection 
associated with higher bacterial burden in distant organs. Type I 
IFN signaling protects the barrier function of the lung during S. 
pneumoniae infection also by promoting survival of the alveolar 
epithelial type II cells as revealed by IFNAR1 deletion specifically 
in this subtype of the barrier epithelium (11).
A common detrimental effect of type I IFN signaling during 
bacterial infections is the induction of various types of leukocyte 
cell death. Type I IFN-facilitated apoptosis of macrophages and 
lymphocytes appears to contribute to the increased susceptibility 
of WT mice compared to IFNAR1-deficient animals to intrave-
nous and intraperitoneal infection with L. monocytogenes (25–27, 
73). Type I IFN-facilitated death of macrophages is associated 
also with harmful effects of type I IFNs during infection with 
F. novicida and S. typhimurium (32, 33). F. novicida promotes 
macrophage death by type I IFN-mediated inflammasome-
activation whereas S. typhimurium employs type I IFN induction 
to stimulate RIP-dependent macrophage necroptosis.
CONClUSiON AND FUTURe DiReCTiONS
Ample evidence exists for the pivotal role of type I IFNs in regu-
lation of defense against bacterial pathogens. The complex and 
often disparate effects of type I IFNs on the outcome of different 
bacterial infections provide chances to exploit type I IFNs and 
their inducers as well as effectors for adjuvant therapies tailored 
to specific infectious diseases. A prerequisite for the development 
of such therapies is a detailed understanding of the molecular, 
cellular, and organismal physiology of type IFNs in the course 
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of bacterial infections. The following topics appear particularly 
important since they represent rather underexplored yet critically 
important areas.
Pathogen Species
The inconsistent roles of type I IFNs during infections with differ-
ent bacteria remain a significant and challenging topic in the cur-
rent research. Only few common principles of type I IFN action 
have been found to date. They include the cell death-promoting 
effects of type I IFNs which contribute mostly to detrimental 
functions of type I IFN signaling. Another frequent observation is 
the suppression of IL-1β and neutrophil chemoattractants—these 
effects are, however, associated with both beneficial and harmful 
consequences for the infection outcome. Future studies employ-
ing pathogens which have not yet been analyzed in detail, such 
as Klebsiella pneumoniae, uropathogenic E. coli, or Clostridium 
difficile, might reveal novel common principles.
infection Route and Tissue-Specific 
Features of Type i iFN Signaling
The complexity of type I IFN function in bacterial infections 
is further increased by the distinct effects of type I IFNs in 
response to the same but differently administered pathogen. 
Type I IFNs are harmful followed intraperitoneal or intravenous 
infection with L. monocytogenes but protective in a physiologi-
cally more relevant intragastric infection (25–28). In contrast, 
type I IFN signaling has no impact on the overall outcome of 
L. monocytogenes infection after ingesting pathogen-contam-
inated food (30). These observations suggest that type I IFN 
signaling has, with regard to bacterial infections, distinct 
functions in different tissues/organs. This implication is sup-
ported by a recent study showing that exogenous type I IFN has, 
depending on the site of administration, disparate effects on the 
course of lung infection with Coxiella burnetii (35). Infections 
with C. burnetii, a Gram-negative intracellular bacterium, in 
humans occur after inhalation of bacteria and result in Q fever 
which can develop into an atypical pneumonia. Lung infec-
tion with C. burnetii in mice has a more severe course in WT 
compared to IFNAR1-deficient animals indicating that type I 
IFN signaling is disadvantageous in this infection model (35). 
Consistently, intraperitoneally administered type I IFN exacer-
bates C. burnetii infection. However, intratracheal delivery of 
type I IFN ameliorates the course of C. burnetii infection. The 
mechanisms of these distinct effects of type I IFN signaling in 
different tissues remain to be elucidated. Future studies should 
investigate other pathogens known of using various routes of 
infection and focus on physiologically most relevant routes.
Most Significant Type i iFN inducers and 
effectors
Modulation of type I IFN production during bacterial infection 
might represent a powerful approach in therapy of infectious dis-
eases. Therapeutic targeting of type I IFN production requires the 
knowledge of the most important type I IFN-inducing pathway in 
a given infection. As most bacterial pathogens employ more than 
one pathway to stimulate type I IFN production, future efforts 
should focus on the identification of the most crucial bacterial 
and cellular components involved in type I IFN induction. These 
studies will need to use a combination of bacterial and animal 
host genetics for functional assessment and suitable reporter as 
well as imaging systems for type I IFN detection in vivo. On the 
effector side, recent studies provided a number of novel type I 
IFN-induced factors which interfere with pathogen replication 
and survival. Notably, various type I IFN-inducible small GTP-
binding proteins have recently been showed to significantly 
contribute to the effects of type I IFNs [e.g., Ref. (74–77)]. These 
and yet to be discovered effectors represent potential targets for 
therapeutic intervention.
Human versus Mouse Systems
While many host defense mechanisms are well conserved among 
mice and men, important differences exist. For example, the 
mouse type I IFN inducer TLR13 is not expressed in humans 
(9, 53). Conversely, the human but not mouse TLR8 appears to 
be involved in type I IFN induction by bacterial RNA (59). Some 
antimicrobial functions of human neutrophils are enhanced by 
type I IFNs (78) whereas such stimulatory effects have so far not 
been described in mouse neutrophils. Future work should put 
more emphasis on studies of common and distinct features of 
type I IFN functions in bacterial infections.
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